

Supplementary Table 1 Full list of patient comorbidities at presentation	
Characteristic	N = 1,190 (%)
Hypertension	717 (60%)
Diabetes Mellitus	451 (38%)
Hyperlipidemia	393 (33%)
Coronary Artery Disease	153 (13%)
Congestive Heart Failure	124 (10%)
Cerebrovascular Accident	100 (8.4%)
COPD or Asthma	202 (17%)
Other Pulmonary Condition	77 (6.5%)
Chronic Kidney Disease	106 (8.9%)
Malignancy	73 (6.1%)
Dementia	125 (11%)
HIV	25 (2.1%)
Hepatitis B or Hepatitis C	24 (2.0%)
IBD	12 (1.0%)
Cirrhosis	17 (1.4%)
Rheumatologic Disease ¹	36 (3.0%)
Transplant ²	50 (4.2%)
¹ Rheumatologic Disease = lupus, rheumatoid arthritis, or other rheumatologic disease	
² Transplant = bone marrow transplant or solid organ transplant	
COPD = chronic obstructive pulmonary disease, HIV = human immunodeficiency virus, IBD = inflammatory bowel disease	

Supplementary Table 2 Baseline characteristics of patients with and without follow-up encounters at our institution		
Characteristic	No Follow-up Encounter	At Least One Follow-up Encounter
	N = 359 (%)	N = 570 (%)
Number of Follow-Up Encounters ¹	0.0 (0.0, 0.0)	3.0 (1.0, 6.0)
Baseline Demographics		
Age ¹	60 (46, 70)	60 (48, 71)
Age: 18-34	37 (10%)	58 (10%)
Age: 35-54	99 (28%)	156 (27%)
Age: 55-64	85 (24%)	138 (24%)

Age: >65	138 (38%)	218 (38%)
BMI¹	28 (25, 34)	28 (25, 33)
<i>Sex at birth</i>		
Male	216 (60%)	326 (57%)
Female	143 (40%)	244 (43%)
<i>Race and Ethnicity</i>		
Hispanic or Latinx Ethnicity	166 (46%)	285 (50%)
Other	139 (39%)	196 (34%)
Not Specified	100 (28%)	144 (25%)
Black	62 (17%)	118 (21%)
White	52 (14%)	104 (18%)
Asian	6 (1.7%)	8 (1.4%)
<i>Smoking Status</i>		
Never smoker	294 (82%)	426 (75%)
Active smoker	19 (5.3%)	28 (4.9%)
Former smoker	44 (12%)	116 (20%)
Medical Comorbidities		
No comorbidity	105 (29%)	114 (20%)
Hypertension	183 (51%)	324 (57%)
Diabetes Mellitus	119 (33%)	200 (35%)
Hyperlipidemia	100 (28%)	185 (32%)
Coronary Artery Disease	23 (6.4%)	69 (12%)
Congestive Heart Failure	26 (7.2%)	54 (9.5%)
Cerebrovascular Accident	23 (6.4%)	36 (6.3%)
COPD or Asthma	55 (15%)	107 (19%)
Other Pulmonary Condition	9 (2.5%)	51 (8.9%)
Chronic Kidney Disease	18 (5.0%)	46 (8.1%)
Malignancy	7 (1.9%)	39 (6.8%)
Dementia	30 (8.4%)	35 (6.2%)
Disposition at Initial Hospitalization		
Emergency Department Visit	62 (17%)	81 (14%)
Hospital Admission	260 (72%)	374 (66%)
ICU Admission	37 (10%)	115 (20%)
<i>Maximum Oxygen Requirement</i>		
No Supplemental Oxygen	118 (33%)	193 (34%)
Nasal Cannula or Venturi Mask	162 (45%)	172 (30%)
HFNC or Non-rebreather Mask	44 (12%)	94 (16%)
Non-invasive Ventilation	1 (0.3%)	4 (0.7%)
Intubation	34 (9.5%)	107 (19%)
¹ Statistics presented: Median (IQR)		
BMI = body mass index; COPD = chronic obstructive pulmonary disease; ICU = intensive care unit; HFNC = high flow nasal cannula.		

Supplementary Table 3 Characteristics of patients discharged before and after the initiation of a systematic hospital-wide COVID-19 discharge approach to provide all patients with follow up appointments		
Characteristic	Discharged before March 26th	Discharged on or after March 26th
	N = 162 (%)	N = 767 (%)
Number of Follow-Up Visits ¹	1.0 (0.0, 4.0)	1.0 (0.0, 4.0)
Any Follow-Up Visit	92 (57%)	478 (62%)
Age ¹	52 (36, 65)	61 (50, 72)
Male	90 (56%)	452 (59%)
Female	72 (44%)	315 (41%)
Any comorbidity	114 (70%)	596 (78%)
¹ Statistics presented: Median (IQR)		

Supplementary Table 4 Persistent symptoms ¹ reported for patients with follow-up encounters, arranged by history of comorbidities ²				
Characteristic	3 months N=488 (%)		6 months N=364 (%)	
	Any Comorbidity N=394 (%)	No Comorbidity N=94 (%)	Any Comorbidity N=308 (%)	No Comorbidity N=56 (%)
No Symptoms	154 (39%)	39 (41%)	122 (40%)	29 (52%)
Cardiopulmonary Symptoms	147 (37%)	27 (29%)	88 (29%)	14 (25%)
Dyspnea	94 (24%)	14 (15%)	50 (16%)	8 (14%)
Cough	62 (16%)	16 (17%)	33 (11%)	4 (7.1%)
Chest Pain	31 (7.9%)	6 (6.4%)	23 (7.5%)	7 (12%)
Lower Extremity Edema	22 (5.6%)	3 (3.2%)	21 (6.8%)	1 (1.8%)
Generalized Symptoms	106 (27%)	18 (19%)	82 (27%)	14 (25%)
Fever	36 (9.1%)	6 (6.4%)	11 (3.6%)	2 (3.6%)
Fatigue	39 (9.9%)	5 (5.3%)	32 (10%)	6 (11%)
Myalgias or Arthralgias	45 (11%)	9 (9.6%)	53 (17%)	11 (20%)
Anosmia or Aguesia	5 (1.3%)	0 (0%)	3 (1.0%)	0 (0%)
Neuropsychiatric Symptoms	85 (22%)	13 (14%)	78 (25%)	10 (18%)
Weakness	34 (8.6%)	7 (7.4%)	30 (9.7%)	4 (7.1%)
Altered Mentation	25 (6.3%)	3 (3.2%)	19 (6.2%)	1 (1.8%)
Headache	23 (5.8%)	3 (3.2%)	17 (5.5%)	4 (7.1%)
Depression or Anxiety	16 (4.1%)	1 (1.1%)	17 (5.5%)	1 (1.8%)
Gait Instability	6 (1.5%)	3 (3.2%)	17 (5.5%)	1 (1.8%)
Gastrointestinal or Urinary Symptoms	59 (15%)	21 (22%)	63 (20%)	12 (21%)
Nausea or Vomiting	22 (5.6%)	4 (4.3%)	19 (6.2%)	4 (7.1%)
Abdominal Pain	20 (5.1%)	5 (5.3%)	29 (9.4%)	5 (8.9%)
Diarrhea	14 (3.6%)	4 (4.3%)	8 (2.6%)	4 (7.1%)
Constipation	10 (2.5%)	6 (6.4%)	7 (2.3%)	1 (1.8%)
Urinary Symptoms	16 (4.1%)	3 (3.2%)	20 (6.5%)	2 (3.6%)
¹ Persistent symptoms = symptoms that did not resolve during each three-month follow-up period				
² Comorbidity = a documented history of any of the following conditions: hypertension, diabetes mellitus, coronary artery disease, heart failure, pulmonary disease, hyperlipidemia, malignancy, chronic or end stage renal disease, cerebrovascular accident, dementia, organ transplant, hepatitis, cirrhosis, inflammatory bowel disease, HIV, or rheumatologic disease (lupus, rheumatoid arthritis, other rheumatologic disease)				